{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:31:47Z","timestamp":1779114707962,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Hematology"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Crovalimab is a novel C5 inhibitor that enables rapid and sustained C5 inhibition with every 4-week subcutaneous maintenance dosing, with the possibility for self-administration. When switching from another C5 inhibitor (binds to a different epitope than crovalimab) to crovalimab and vice versa, transient immune complexes will form and may cause transient immune complex reactions (TICRs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>To assess TICR occurrence, manifestation, and management in patients with paroxysmal nocturnal hemoglobinuria (PNH) who switched from another C5 inhibitor to crovalimab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>COMMODORE 1 and 2 randomized C5 inhibitor-experienced and -na\u00efve patients, respectively, to receive crovalimab or eculizumab. The COMMODORE 1 nonrandomized, descriptive cohort included patients who previously received ravulizumab or approved or higher-than-approved doses of eculizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Pooled data of patients who switched from eculizumab or ravulizumab to crovalimab were evaluated for TICR incidence and severity. TICR treatments and TICR durations were assessed by severity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      This descriptive analysis included 201 patients who switched from eculizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009174) or ravulizumab (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927) to crovalimab. Baseline characteristics were generally balanced between patients with and without a TICR. Thirty-nine of 201 patients (19%) experienced TICRs (11% Grades 1\u20132; 8% Grade 3; no Grades 4\u20135). Median time to onset and median TICR duration were 1.6 (range, 0.7\u20134.4) and 1.7\u2009weeks (range, 0.4\u201334.1), respectively. The most common symptoms were arthralgia (45%), rash (34%), and pyrexia (21%), with no evidence of renal manifestations. Oral corticosteroids were the most common TICR treatment. Grade 3 TICRs were treated with higher oral corticosteroid dose but did not take longer to resolve than Grades 1\u20132 TICRs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pooled COMMODORE 1 and 2 data show that TICRs from switching between C5 inhibitors were generally mild to moderate and resolved with appropriate treatment. These results further confirm that crovalimab is well tolerated in patients with PNH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration:<\/jats:title>\n                    <jats:p>NCT04432584; NCT04434092.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/20406207251359246","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T04:42:58Z","timestamp":1758170578000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["Managing transient immune complex reactions in patients with paroxysmal nocturnal hemoglobinuria: clinical observations from the COMMODORE 1 and 2 studies"],"prefix":"10.1177","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3180-3570","authenticated-orcid":false,"given":"Austin G.","family":"Kulasekararaj","sequence":"first","affiliation":[{"name":"Department of Haematological Medicine, King\u2019s College Hospital, Denmark Hill, London SE5 9RS, UKNational Institute for Health Research and Wellcome King\u2019s Clinical Research Facility and King\u2019s College London, Denmark Hill, London SE5 9RS, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun-Ichi","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Osaka University Graduate School of Medicine, Osaka, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"R\u00f6th","sequence":"additional","affiliation":[{"name":"Department of Hematology and Stem Cell Transplantation, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leigh","family":"Beveridge","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Buatois","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Buri","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolo","family":"Compagno","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Luder","sequence":"additional","affiliation":[{"name":"F. Hoffmann-La Roche Ltd., Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sasha","family":"Sreckovic","sequence":"additional","affiliation":[{"name":"Genentech, Inc., South San Francisco, CA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip","family":"Scheinberg","sequence":"additional","affiliation":[{"name":"Division of Hematology, Hospital A Benefic\u00eancia Portuguesa, S\u00e3o Paulo, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,9,17]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061648"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876136"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-876805"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-333997"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13783"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17753"},{"key":"e_1_3_4_8_2","unstructured":"Chugai Pharmaceutical Co. Ltd. Chugai obtains regulatory approval for \u201cPiasky 340 mg\u201d for paroxysmal nocturnal hemoglobinuria in Japan https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20240326160001_1056.html (2024 accessed 1 April 2024)."},{"key":"e_1_3_4_9_2","unstructured":"Chugai Pharmaceutical Co. Ltd. Crovalimab approved in China as the first country for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) https:\/\/www.chugai-pharm.co.jp\/english\/news\/detail\/20240208113000_1047.html?year=2024&category= (2024 accessed 27 February 2024)."},{"key":"e_1_3_4_10_2","volume-title":"PiaSky (prescribing information)","author":"Genentech, Inc","year":"2024","unstructured":"Genentech, Inc. PiaSky (prescribing information). South San Francisco, CA: Genentech, Inc., 2024."},{"key":"e_1_3_4_11_2","volume-title":"PiaSky (summary of product characteristics)","author":"Roche Registration GmbH","year":"2024","unstructured":"Roche Registration GmbH. PiaSky (summary of product characteristics). Grenzach-Wyhlen, Germany: Roche Registration GmbH, 2024."},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01087-7"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003399"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252111679"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2851"},{"key":"e_1_3_4_16_2","unstructured":"Vaillant A Vashisht R Zito P. Immediate hypersensitivity reactions https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30020687 (2024 accessed 8 February 2024)."},{"key":"e_1_3_4_17_2","unstructured":"Usman N Annamaraju P. Type III hypersensitivity reaction https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32644548 (2024 accessed 8 February 2024)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27412"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27413"},{"key":"e_1_3_4_20_2","unstructured":"US Department of Health and Human Services NIoH National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5 https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events (2017 accessed July 2025)."},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003258651"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780199235339.001.0001"},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semerg.2018.01.011"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029618764843"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1159\/000439032"},{"key":"e_1_3_4_26_2","unstructured":"Wener MH. Serum sickness and serum sickness-like reactions https:\/\/www.uptodate.com\/contents\/serum-sickness-and-serum-sickness-like-reactions (2022 accessed November 2024)."},{"key":"e_1_3_4_27_2","unstructured":"Quirt J Rogala B Cichocka-Jarosz E. Serum sickness https:\/\/empendium.com\/mcmtextbook-sae\/chapter\/B78.II.17.2.?rfmcm (2022 accessed November 2024)."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.21098"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.14744\/hnhj.2023.70846"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1081-1206(10)63308-X"},{"key":"e_1_3_4_31_2","unstructured":"Sicari V Zabbo C. Diphenhydramine https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK526010\/ (2023 accessed November 2024)."},{"key":"e_1_3_4_32_2","volume-title":"Cetirizine hydrochloride (summary of product characteristics)","author":"Dr. Reddy\u2019s Laboratories (UK) Ltd","year":"2024","unstructured":"Dr. Reddy\u2019s Laboratories (UK) Ltd. Cetirizine hydrochloride (summary of product characteristics). Cambridge, UK: Dr. Reddy\u2019s Laboratories (UK) Ltd., 2024."},{"key":"e_1_3_4_33_2","volume-title":"Ibuprofen (summary of product characteristics)","author":"Aurobindo Pharma\u2014Milpharm Ltd","year":"2024","unstructured":"Aurobindo Pharma\u2014Milpharm Ltd. Ibuprofen (summary of product characteristics). Middlesex, UK: Aurobindo Pharma\u2014Milpharm Ltd., 2024."},{"key":"e_1_3_4_34_2","volume-title":"Loratadine (summary of product characteristics)","author":"Sun Pharmaceutical Industries Ltd","year":"2024","unstructured":"Sun Pharmaceutical Industries Ltd. Loratadine (summary of product characteristics). Uxbridge, UK: Ranbaxy (UK) Sun Pharmaceutical Industries Ltd., 2024."},{"key":"e_1_3_4_35_2","volume-title":"Naproxen (summary of product characteristics)","author":"Strides Pharma UK Ltd","year":"2024","unstructured":"Strides Pharma UK Ltd. Naproxen (summary of product characteristics). Hertfordshire, UK: Strides Pharma UK Ltd., 2024."},{"key":"e_1_3_4_36_2","volume-title":"Paracetamol (summary of product characteristics)","author":"Zentiva","year":"2023","unstructured":"Zentiva. Paracetamol (summary of product characteristics). Surrey, UK: Zentiva, 2023."},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1159\/000538241"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-200400"}],"container-title":["Therapeutic Advances in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251359246","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20406207251359246","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20406207251359246","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:17:52Z","timestamp":1777591072000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20406207251359246"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":37,"alternative-id":["10.1177\/20406207251359246"],"URL":"https:\/\/doi.org\/10.1177\/20406207251359246","relation":{},"ISSN":["2040-6207","2040-6215"],"issn-type":[{"value":"2040-6207","type":"print"},{"value":"2040-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"20406207251359246"}}